参考文献/References:
[1] 杭远远,金毓莉.中医药在体外受精-胚胎移植中的应用及机制研究概述[J].陕西中医,2019,40(11):1649-1652.
[2] Poseidon G,Alviggi C,Andersen CY,et al.A new more detailed stratification of low responders to ovarian stimulation:From a poor ovarian response to a low prognosis concept[J].Fertil Steril,2016,105(6):1452-1453.
[3] 张 蕾,惠立本.女性生殖器结核不孕患者超声特征及其与卵巢储备功能相关性研究[J].陕西医学杂志,2022,51(10):1263-1266.
[4] Tesarik J,Galan-Lazaro M,Mendoza-Tesarik R.Ovarian aging:Molecular mechanisms and medical management[J].Int J Mol Sci,2021,22(3):1371.
[5] Lliodromiti S,Lglesias SC,Messow CM,et al.Excessive age-related decline in functional ovarian reserve in infertile women:Prospective cohort of 15 500 women[J].J Clin Endocrinol Metab,2016,101(9):3548-3554.
[6] Adebayo FO,Ameh N,Adesiyun AG,et al.Correlation of female age with outcome of IVF in a low-resource setting[J].Int J Gynaecol Obstet,2022,1(1):1-8.
[7] 马姣荣,刘成云.促性腺激素释放激素激动剂对保留卵巢根治术患者卵巢功能的影响[J].陕西医学杂志,2020,49(1):24-26,36.
[8] Lee RWK,Khin LW,Hendricks MS,et al.Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore[J].Singapore Med J,2020,61(9):463-468.
[9] Zhou SJ,Zhao MJ,Li C,et al.The comparison of evaluative effectiveness between antral follicle count/age ratio and ovarian response prediction index for the ovarian reserve and response functions in infertile women[J].Medicine(Baltimore),2020,99(36):21979.
[10] Jadaon JE,Ben-Ami M,Haddad S,et al.Prospective evaluation of early follicular ovarian stromal blood flow in infertile women undergoing IVF-ET treatment[J].Gynecol Endocrinol,2012,28(5):356-359.
[11] Bunnewell SJ,Honess ER,Karia AM,et al.Diminished ovarian reserve in recurrent pregnancy loss:A systematic review and meta-analysis[J].Fertil Steril,2020,113(4):818-827.
[12] Atasever M,Soyman Z,Demirel E,et al.Diminished ovarian reserve:Is it a neglected cause in the assessment of recurrent miscarriage?A cohort study[J].Fertil Steril,2016,105(5):1236-1240.
[13] Wang J,Lv Y,Wang X,et al.Retrospective study of ovarian reaction and fertility in women with discordant antimullerian hormone and follicle-stimulating hormone/luteinizing hormone ratios during in vitro fertilization[J].J Obstet Gynaecol Res,2023,1(1):1-7.
[14] Wen J,Huang K,Du X,et al.Can inhibin B reflect ovarian reserve of healthy reproductive age women effectively?[J].Front Endocrinol(Lausanne),2021,12(1):1-10.
[15] Sinha S,Sharan A,Sinha S.Anti-mullerian hormone as a marker of ovarian reserve and function[J].Cureus,2022,14(9):29214-29225.
[16] Tal R,Seifer DB,Tal R,et al.AMH highly correlates with cumulative live birth rate in women with diminished ovarian reserve independent of age[J].J Clin Endocrinol Metab,2021,106(9):2754-2766.
[17] Zhang Y,Zhang C,Shu J,et al.Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF:A systematic review and network meta-analysis[J].Hum Reprod Update,2020,26(2):247-263.
[18] Xu H,Feng G,Wang H,et al.A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response:A retrospective cohort study[J].J Assist Reprod Genet,2020,37(4):963-972.
[19] 马新想,崔海玲,张富青.滋肾育胎丸对不孕症患者卵巢储备功能及妊娠结局的影响[J].陕西中医,2019,40(2):198-200.
[20] Hu L,Zhang S,Quan S,et al.Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization-embryo transfer[J].Aging(Albany NY),2020,12(6):4918-4930.
[21] Jiang S,Kuang Y.The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization[J].Clin Endocrinol(Oxf),2018,88(1):77-87.
[22] Moffat R,Hansali C,Schoetzau A,et al.Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders[J].Hum Reprod,2021,36(4):987-997.
[23] Ntostis P,Iles D,Kokkali G,et al.The impact of maternal age on gene expression during the GV to MII transition in euploid human oocytes[J].Hum Reprod,2021,37(1):80-92.
[24] Kol S.LH supplementation in ovarian stimulation for IVF:The individual,LH deficient,patient perspective[J].Gynecol Obstet Invest,2020,85(4):307-311.
[25] Seshadri S,Morris G,Serhal P,et al.Assisted conception in women of advanced maternal age[J].Best Pract Res Clin Obstet Gynaecol,2021,70(1):10-20.
[26] Wang R,Lin S,Wang Y,et al.Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve:A systematic review and meta-analysis[J].PLoS One,2017,12(4):1-19.
[27] Ovarian ST,Bosch E,Broer S,et al.ESHRE guideline:Ovarian stimulation for IVF/ICSI(dagger)[J].Hum Reprod Open,2020,2020(2):9-21.
[28] Moini A,Lavasani Z,Kashani L,et al.Letrozole as co-treatment agent in ovarian stimulation antagonist protocol in poor responders:A double-blind randomized clinical trial[J].Int J Reprod Biomed,2019,17(9):653-6560.
[29] Zhang S,Gao F,Fu M,et al.Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles[J].Front Med(Lausanne),2022,9:1070583.
[30] 曲丹妮,王 鹏,李 媛.促性腺激素释放激素激动剂在体外受精-胚胎移植患者黄体支持中的应用[J].吉林大学学报:医学版,2021,47(3):701-706.
[31] 高任远.波塞冬标准下卵巢低反应患者黄体期促排卵囊胚形成率的比较[D].济南:山东大学,2020.
[32] Chen Q,Wang Y,Sun L,et al.Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders[J].Reprod Biol Endocrinol,2017,15(1):71-78.
[33] Chen Q,Chai W,Wang Y,et al.Progestin vs.gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment:A randomized controlled trial[J].Front Endocrinol(Lausanne),2019,10(1):796-805.
[34] 李婉晴,洪名云,唐志霞.预期卵巢低反应患者不同促排卵方案的结局分析[J].国际生殖健康/计划生育杂志,2022,41(1):1-5.
[35] Marco MP,Montanari G,Ruscito I,et al.Natural cycle results in lower implantation failure than ovarian stimulation in advanced-age poor responders undergoing ivf:Fertility outcomes from 585 patients[J].Reprod Sci,2021,28(7):1967-1973.
[36] Gleicher N,Darmon SK,MolinarI E,et al.Importance of IGF-I levels in IVF:Potential relevance for growth hormone(GH)supplementation[J].J Assist Reprod Genet,2022,39(2):409-416.
[37] Noventa M,Vitagliano A,Andrisani A,et al.Testosterone therapy for women with poor ovarian response undergoing IVF:A meta-analysis of randomized controlled trials[J].J Assist Reprod Genet,2019,36(4):673-683.
[38] Gizzo S,Capuzzo D,Zicchina C,et al.Could empirical low-dose-aspirin administration during IVF cycle affect both the oocytes and embryos quality via COX 1-2 activity inhibition?[J].J Assist Reprod Genet,2014,31(3):261-268.
[39] Zheng M,Tong J,Li WP,et al.Melatonin concentration in follicular fluid is correlated with antral follicle count(AFC)and in vitro fertilization(IVF)outcomes in women undergoing assisted reproductive technology(ART)procedures[J].Gynecol Endocrinol,2018,34(5):446-450.
[40] Ma L,Cai L,Hu M,et al.Coenzyme Q10 supplementation of human oocyte in vitro maturation reduces postmeiotic aneuploidies[J].Fertil Steril,2020,114(2):331-337.
[41] 孙晓晓,张翠莲.抗氧化剂在高龄不孕女性中的应用研究进展[J].医药论坛杂志,2020,41(4):174-177.